Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

INC Research Strengthens Asia/Pacific Capabilities Through Two New Offices in Japan


Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-07-29 22:35:04 -

Offices in Osaka and Shinagawa in Tokyo provide strong clinical development hub
          for customers in world's second largest pharmaceutical market

Raleigh, NC, July 29, 2013 - INC Research LLC, a therapeutically focused global
clinical research organization (CRO) with a Trusted Process® for delivering
reliable results, today announced the establishment of INC Research Japan KK
with the opening of new locations in Osaka and the Shinagawa ward in Tokyo. The
new operations provide INC Research's global drug development customers access
to an increasingly significant market and further expand the Company's presence
in the Asia/Pacific region. INC Research now has 20 offices in key locations
across the Asia/Pacific region in addition to Japan, including a presence in
China, India, Australia, Singapore, Philippines, South Korea, 
Taiwan, Hong Kong, Malaysia, Thailand, Indonesia and New Zealand. "There is a growing enthusiasm from both pharma and government sectors for Japan to be involved in both global and regional clinical trials," said Garth Tierney , Executive Vice President, Asia/Pacific. "In response, INC Research is implementing a very considered approach to the market that will create greater confidence among our customers in conducting trials in Japan, as well as ultimately provide more direct influence on how trials are conducted. Our Japanese customers already have responded positively to our Trusted Process methodology as it fits well with their requirements for high quality and predictability. We are very enthusiastic about bringing the continued benefits of drug development in this country to our customers." Through INC Research's unique approach to the Japan market, the two offices initially will feature a core group of highly qualified, English-speaking management, regulatory and therapeutic staff who will create a bridge between the Company's Trusted Process methodology and the way clinical research has traditionally been conducted in Japan. The establishment of Japanese business operations builds on INC Research's long-term experience in Japan where it has partnered with local CROs to conduct numerous trials across a variety of therapeutic areas. The Osaka office is located at Level 19  Hilton Plaza West Office Tower, 2-2-2 UMEDA, Kita-ku, Osaka 530-0001 and the Tokyo office is located at Level 28 Shinagawa Intercity Tower A, 2-15-1 Konan Minato-ku, Tokyo 108-6028. Both locations are strategically placed to serve major drug development areas and are connected by the region's bullet train. INC Research has provided Phase I to IV clinical development services in the Asia/Pacific region for nearly 20 years , conducting more than a 1,000 studies across a broad range of therapeutic areas. For more information on INC Research's clinical trial services and experience in Japan, please call +81-6-6450 9360 or visit the website. About INC Research INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research. Contact: Lori Dorer, Media +1 (513) 345-1685 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: INC RESEARCH, LLC via Thomson Reuters ONE [HUG#1719617]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com